Growth Drivers on Track – Operational Turnaround Expected in 2021
We reiterate our “Overweight” rating on the stock post 1H FY18 (YE Dec-18) earnings1H FY18 Results Highlights Symbio reported an increase in 1H...
491 Views
SymBio Pharmaceuticals - Self-commercialization gains favor
With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to...
165 Views
SymBio Pharmaceuticals - Self-commercialisation gains favour
With the lifecycle of Treakisym extended through the in-licensing of liquid formulations from Eagle in 2017, SymBio is refining its plans to...
108 Views
Symbio Pharma (4582 JP) -Â Gross Margin Expansion Led Operational Turnaround in 2021
2020 – an inflection point for Symbio Treakisym (bendamustine), Symbio’s only revenue driver currently, is marketed by Eisai in Japan for r/r NHL....
259 Views
SymBio Pharmaceuticals - Licence agreement for IONSYS terminated
The licence agreement between SymBio and The Medicines Company (MDCO) for the exclusive rights to develop the IONSYS (SyB P-1501) pain patch in...
153 Views